MA33555B1 - Procédés et compositions pour traiter la leucémie - Google Patents
Procédés et compositions pour traiter la leucémieInfo
- Publication number
- MA33555B1 MA33555B1 MA34609A MA34609A MA33555B1 MA 33555 B1 MA33555 B1 MA 33555B1 MA 34609 A MA34609 A MA 34609A MA 34609 A MA34609 A MA 34609A MA 33555 B1 MA33555 B1 MA 33555B1
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- treating leukemia
- leukemia
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une combinaison d'un inhibiteur de bcr-abl et d'un inhibiteur de voie hedgehog pour le traitement de la leucémie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/539,855 US20110039850A1 (en) | 2009-08-12 | 2009-08-12 | Leukemia Treatment |
PCT/US2010/045133 WO2011019798A1 (fr) | 2009-08-12 | 2010-08-11 | Procédés et compositions pour traiter la leucémie |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33555B1 true MA33555B1 (fr) | 2012-09-01 |
Family
ID=42727621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34609A MA33555B1 (fr) | 2009-08-12 | 2012-02-07 | Procédés et compositions pour traiter la leucémie |
Country Status (19)
Country | Link |
---|---|
US (3) | US20110039850A1 (fr) |
EP (1) | EP2464423A1 (fr) |
JP (1) | JP2013501798A (fr) |
KR (1) | KR20120089844A (fr) |
CN (2) | CN103736094A (fr) |
AU (1) | AU2010282547A1 (fr) |
BR (1) | BR112012003278A2 (fr) |
CA (1) | CA2769300A1 (fr) |
CL (1) | CL2012000350A1 (fr) |
IL (1) | IL217764A0 (fr) |
MA (1) | MA33555B1 (fr) |
MX (1) | MX2012001846A (fr) |
NZ (1) | NZ597864A (fr) |
PH (1) | PH12014500538A1 (fr) |
RU (1) | RU2012108930A (fr) |
SG (2) | SG178082A1 (fr) |
TN (1) | TN2012000029A1 (fr) |
WO (1) | WO2011019798A1 (fr) |
ZA (1) | ZA201200434B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104262262B (zh) * | 2014-08-29 | 2016-06-08 | 西安交通大学 | 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用 |
PL3700902T3 (pl) | 2017-10-27 | 2023-09-04 | Boehringer Ingelheim International Gmbh | Inhibitory trpc6 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
PE20090188A1 (es) * | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
CN101820950B (zh) * | 2007-06-07 | 2015-01-21 | Irm责任有限公司 | 作为刺猬蛋白信号通路调节剂的联苯基甲酰胺类化合物 |
EP2187967B1 (fr) * | 2007-08-16 | 2013-04-24 | Irm Llc | Procédés et compositions pour traiter des cancers |
WO2010030948A2 (fr) * | 2008-09-12 | 2010-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Signalisation hedgehog et cellules souches cancéreuses dans des malignités de cellules hématopoïétiques |
-
2009
- 2009-08-12 US US12/539,855 patent/US20110039850A1/en not_active Abandoned
-
2010
- 2010-08-11 JP JP2012524831A patent/JP2013501798A/ja active Pending
- 2010-08-11 RU RU2012108930/15A patent/RU2012108930A/ru not_active Application Discontinuation
- 2010-08-11 MX MX2012001846A patent/MX2012001846A/es not_active Application Discontinuation
- 2010-08-11 EP EP10747112A patent/EP2464423A1/fr not_active Withdrawn
- 2010-08-11 CA CA2769300A patent/CA2769300A1/fr not_active Abandoned
- 2010-08-11 NZ NZ597864A patent/NZ597864A/en not_active IP Right Cessation
- 2010-08-11 SG SG2012004685A patent/SG178082A1/en unknown
- 2010-08-11 CN CN201310751285.8A patent/CN103736094A/zh active Pending
- 2010-08-11 AU AU2010282547A patent/AU2010282547A1/en not_active Abandoned
- 2010-08-11 KR KR1020127006236A patent/KR20120089844A/ko not_active Application Discontinuation
- 2010-08-11 BR BR112012003278A patent/BR112012003278A2/pt not_active IP Right Cessation
- 2010-08-11 SG SG10201407435WA patent/SG10201407435WA/en unknown
- 2010-08-11 WO PCT/US2010/045133 patent/WO2011019798A1/fr active Application Filing
- 2010-08-11 CN CN2010800458363A patent/CN102695547A/zh active Pending
-
2012
- 2012-01-19 ZA ZA2012/00434A patent/ZA201200434B/en unknown
- 2012-01-20 TN TNP2012000029A patent/TN2012000029A1/en unknown
- 2012-01-26 IL IL217764A patent/IL217764A0/en unknown
- 2012-02-07 MA MA34609A patent/MA33555B1/fr unknown
- 2012-02-10 CL CL2012000350A patent/CL2012000350A1/es unknown
- 2012-08-28 US US13/596,176 patent/US20120329798A1/en not_active Abandoned
-
2014
- 2014-03-10 PH PH12014500538A patent/PH12014500538A1/en unknown
-
2015
- 2015-04-08 US US14/681,431 patent/US20150209365A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112012003278A2 (pt) | 2016-03-01 |
ZA201200434B (en) | 2012-10-31 |
SG178082A1 (en) | 2012-03-29 |
NZ597864A (en) | 2014-01-31 |
KR20120089844A (ko) | 2012-08-14 |
EP2464423A1 (fr) | 2012-06-20 |
CN102695547A (zh) | 2012-09-26 |
JP2013501798A (ja) | 2013-01-17 |
TN2012000029A1 (en) | 2013-09-19 |
CL2012000350A1 (es) | 2012-10-12 |
AU2010282547A1 (en) | 2012-02-16 |
WO2011019798A1 (fr) | 2011-02-17 |
CN103736094A (zh) | 2014-04-23 |
SG10201407435WA (en) | 2014-12-30 |
CA2769300A1 (fr) | 2011-02-17 |
MX2012001846A (es) | 2012-05-22 |
RU2012108930A (ru) | 2013-09-20 |
US20120329798A1 (en) | 2012-12-27 |
IL217764A0 (en) | 2012-03-29 |
PH12014500538A1 (en) | 2015-09-07 |
US20110039850A1 (en) | 2011-02-17 |
US20150209365A1 (en) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR23C1003I2 (fr) | Compositions et leurs utilisations pour le traitement de la Sclérose en plaques | |
MA35210B1 (fr) | Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer | |
MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
FR2932478B1 (fr) | Composes utiles pour le traitement des cancers. | |
MX2009013082A (es) | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. | |
JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
MA32748B1 (fr) | Traitement du cancer de l'utérus du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux | |
ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
MA38495A1 (fr) | Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA38959A1 (fr) | Modulateurs du facteur b du complément | |
MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
EA201170832A1 (ru) | Пуриновые соединения | |
MX360301B (es) | Moleculas pequeñas que contienen boro como agentes antiinflamatorios. | |
EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
MA34598B1 (fr) | Procédés et compositions pour traiter le cancer du poumon | |
FR2912761B1 (fr) | Tricot prothetique pour le traitement des prolapsus | |
MA33739B1 (fr) | Procédés et compositions pour traiter des tumeurs solides et d'autres malignités | |
EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
MA33423B1 (fr) | Différentiation de cellules souches mésenchymateuses | |
FR2907011B1 (fr) | Utilisation de la citrulline pour le traitement des etats de denutrition | |
TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
MY150600A (en) | Use of opioid antagonists for treating urinary retention | |
MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. |